VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway

Hepatocellular Carcinoma Clinical Trial

— HCC  

Official title:

VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01892072
• Other study ID #: k0113011-2013VEGF
• Status: Active, not recruiting
• Phase: N/A
• First received: June 30, 2013
• Last updated: July 10, 2013
• Start date: October 2012
• Est. completion date: March 2014

Study information

• Verified date: July 2013
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ministry of Science and Technology
• Study type: Observational

Clinical Trial Summary

The investigators study the VEGF signaling in HCC cell lines and its mechanism in HCC growth, proliferation and apoptosis.

Description:

Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in HCC cell lines and tumor tissues. Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage HCC. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in HCC cells and its possible mechanism in regulating HCC growth.Therefore,we try to clarify the mechanism of VEGF signal in HCC growth,proliferation and apoptosis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 50
• Est. completion date: March 2014
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years to 80 Years

Eligibility

Inclusion Criteria:

1. hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of hepatocellular carcinoma and alphafetoprotein>400µg/L;or two or more dynamic imagine with a diagnosis of hepatocellular carcinoma

2. Child-Pugh A or B

3. well preserved renal and hematopoietic Function

4. receive surgical therapy

5. achieve complete section accessed by contrast-enhanced CT

Exclusion Criteria:

1. incomplete section

2. remote metastasis

3. Child-Pugh C

4. combination with other hepatobiliary disease

5. suffer from other tumors concurrently or in last five years

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Procedure:
• surgical treatment
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.

Locations

Country	Name	City	State
China	First Affiliated Hospital, Sun Yat-Sen University	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
First Affiliated Hospital, Sun Yat-Sen University	Guangdong Province, Department of Science and Technology

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.	the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have).	the day when conducting surgery (day 1)	No